Skip to main content
. 2016 Nov 30;8(2):3274–3288. doi: 10.18632/oncotarget.13712

Figure 5. Anti-ENO1 Ab reactivity is associated with parameters of progressive disease and with a shorter TTFT in patients with CLL.

Figure 5

The presence of circulating anti-ENO1 Ab in sera of patients with CLL was correlated with parameters of disease progression and TTFT. Anti-ENO1 Ab were more frequently detected in sera from patients with progressive CLL than in sera from patients with stable CLL (p<0.0001) (A). Kaplan-Meier survival curves for TTFT in our cohort of patients stratified on the basis of anti-ENO1 reactivity are shown. The presence of anti-ENO1 Ab correlated with shorter TTFT (ENO1 Ab+, n=19; ENO1 Ab-, n=16) (p=0.01) (B).